Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: A new face of cure, an expert review

Expert Review of Anti-Infective Therapy

Volumn 14, Issue 2, 2016, Pages 157-165

  Mantry, Parvez S ^a   Pathak, Lakshmikant ^a  

^a METHODIST DALLAS MEDICAL CENTER   (United States)

Author keywords

3D; ABT 333; ABT 450; Dasabuvir; direct antiviral agents (DAA); HCV; polymerase inhibitor; sustained virological response (SVR)

Indexed keywords

DASABUVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; HEPACIVIRIN INHIBITOR; NONSTRUCTURAL PROTEIN 5B; OMBITASVIR; PARITAPREVIR PLUS RITONAVIR; PEGINTERFERON; PLACEBO; RIBAVIRIN; UNCLASSIFIED DRUG; ABT-333; ANTIVIRUS AGENT; DRUG COMBINATION; INTERFERON; MACROCYCLIC COMPOUND; RITONAVIR; SULFONAMIDE; URACIL;

ANTIVIRAL RESISTANCE; ARTICLE; ASTHENIA; CHRONIC HEPATITIS C; COUGHING; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HEADACHE; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MIXED INFECTION; NAUSEA; NONHUMAN; PRURITUS; RASH; RELAPSE; SKIN MANIFESTATION; VIRUS LOAD; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; VIROLOGY;

ANTIVIRAL AGENTS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MACROCYCLIC COMPOUNDS; RIBAVIRIN; RITONAVIR; SULFONAMIDES; URACIL;

EID: 84957434752     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2016.1120668     Document Type: Article

References (29)

1. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011;140 (4):1182-8
2. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26:401-412
3. Ferrari SM, Fallahi P, Mancusi C, et al. HCV-related autoimmune disorders in HCV chronic infection. Clin Ter. 2013;164: e305-12
4. Kiser JJ, Flexner C. Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-449
5. Borgia G, Reynauds L, Gentile I, et al. Myasthenia gravis during low dose IFN alpha therapy for chronic hepatitis C. j Interferon. Cytokine Res. 2001;21(7):469-470
6. Gentile I, Viola C, Reynaud L, et al. Hemolytic anemia during Pegylated IFN-alpha 2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit. J Interferon Cytokine Res. 2005;25(5):283-285
7. Tosone G, Borgia G, Gentile I, et al A case of Pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided?. Acta Diabetol. 2007;44 (3):167-169
8. Gentile Viola C, Borgia F, et al. The efficacy and safety of telaprevir-A new protease inhibitor gainst hepatitis C virus. Expert Opin Investig Drugs. 2010;19(1):151-159
9. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374
10. Coppola N, Pisaturo M, Sagnelli C, et al Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV Genotype 1: a meta-analysis on the role of response predictors. PLoS ONE. 2014;9:4
11. Gentile I, Buonomo AR, Borgia G. Dasabuvir: a nonnucleoside inhibitor of NS5B for the treatment of Hepatitis C virus infection. Rev Recent Clin Trials. 2014;9:115-123
12. Pockros PJ. Nucleoside/Nucleotide analogue polymerase inhibitors in development. Clin Liver Dis. 2013;17:105-110
13. Au JS, Pockros PJ. Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther. 2014;95(1):78-88
14. Soriano V, Vispo E, Mendoza C, et al Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother. 2013;14:1161-1170
15. Kwo PY, Vinayek R. The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors. Gut Liver. 2011;5(4):406-417
16. Manns MP, Von Hahn T. Novel therapies for hepatitis C-one pill fits all?. Nat Rev Drug Discov. 2013;12 (8):595-610
17. Maring C, Wagner R, Hutchinson D, et al. Preclinical potency, pharmacokinetic and ADME characterization of ABT-333,a novel non-nucleoside HCV polymerase inhibitor. J Hepatol. 2009;50:S347-S
18. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/rombitasv and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604-1614
19. Rodriguez-Torres M, Lawitz E, Cohen D. Treatment-naïve, HCV genotype 1-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peg interferon and ribavirin compared to peg interferon and ribavirin alone. Hepatology. 2009;50(Suppl 4):91A
20. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and Dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973-1982
21. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375-2382
22. Ferenci P, et al. ABT-450/r-Ombitasvir and Dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983-1992. PEARL III and IV
23. Ferenci P, Nyberg A, Enayati P, et al. PEARL III: 12 weeks of ABT-450/R/267 + ABT-333 achieved SVR in 99% of 419 treatment-naive HCV genotype 1Binfected adults with or without ribavirin. J Hepatol. 2014;60(1):S527
24. Feld JJ, Kowdley KV, Coakley E, et al Treatment of HCV with ABT-450/r-Ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594-1603
25. Gaultier I, Cohen D, Dumas E, et al. 12-week efficacy and safety of ABT-072 or ABT-333 with Pegylated interferon + ribavirin, following 3-day monotherapy in genotype 1 HCV infected treatment-naive subjects [abstract1329]. 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL); 17-20 February2011; Bangkok, Thailand
26. Pilot-Matias T, Koev G, Krishnan P, et al. In vitro combinatory effect of HCV NS3/4A protease inhibitor ABT-450, NS5A inhibitor ABT-267 and non nucleoside NS5B polymerase inhibitor ABT-333. J Hepatol. 2012;56:S338-S38
27. Eron JJ, Lalezari J, Slim J, et al. Safety and efficacy of Ombitasvir-450/r and dasabuvir and ribavirin in HCV/ HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens. J Int AIDS Soc. 2014;17(4 Suppl 3):19500
28. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368(1):45-53
29. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C Virus genotype 1. N Engl J Med. 2014;370(3):222-232